BIOGEN INC. (BIIB)

197 1.38 (0.71%)

As of 2026-02-18 02:37:25 EST

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis (collectively 45% of 2024 revenues); nusinersen (Spinraza) for the treatment of spinal muscular atrophy (16.2% of 2024 revenues); omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia (4.0% of 2024 revenues); tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars (8.2% of 2024 revenues) and has collaborations with Genentech for several drugs (18.1% of 2024 revenues).

Traded asNasdaq: BIIB
ISINUS09062X1037
CIK0000875045
LEIW8J5WZB5IY3K0NDQT671
EIN330112644
SectorBiotechnology
IndustryBiological Products, (No Diagnostic Substances)
CEOChris Viehbacher
Employees7,605
Fiscal Year End1231
Address225 BINNEY STREET, CAMBRIDGE, MA, 02142
Phone7814642000
Websitehttps://biogen.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
BIIBBIOGEN INC.2026-02-18 02:37:251971.380.71
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
BIIB0000875045BIOGEN INC.US09062X1037W8J5WZB5IY3K0NDQT671330112644Nasdaq2836Biological Products, (No Diagnostic Substances)1231DE225 BINNEY STREETCAMBRIDGEMA02142UNITED STATESUS7814642000225 BINNEY STREET, CAMBRIDGE, MA, 02142225 BINNEY STREET, CAMBRIDGE, MA, 02142BIOGEN IDEC INC.Biotechnology1978Chris Viehbacher7,605https://biogen.com18,378,285,308170,500,000146,758,528Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis (collectively 45% of 2024 revenues); nusinersen (Spinraza) for the treatment of spinal muscular atrophy (16.2% of 2024 revenues); omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia (4.0% of 2024 revenues); tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars (8.2% of 2024 revenues) and has collaborations with Genentech for several drugs (18.1% of 2024 revenues).2026-02-12 15:37:17
This is a preview of the latest data. Subscribe to access the full data.
BIIB Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
BIIB Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
202518,378,285,308-15,331,469,759-45.4808146,758,528383,5910.2621
202433,709,755,067-7,481,113,733-18.1621146,374,9371,014,1390.6977
202341,190,868,80011,792,903,98240.1147145,360,798875,1520.6057
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Susan H. AlexanderChief Legal Officer, Executive Vice President2024954,19203,879,2191,516,537155,8816,505,829
Christopher A. ViehbacherCEO, President20241,600,000018,010,9114,308,480243,70124,166,665
Michael R. McdonnellChief Financial Officer, Executive Vice President2024992,53104,433,8621,211,989187,2966,826,734
Michael R. McdonnellChief Financial Officer, Executive Vice President2023945,26804,960,6291,129,183131,6847,167,601
Christopher A. ViehbacherCEO, President20231,600,000002,376,00093,8744,069,913
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
20257,500
20247,605
20237,570
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue9,890,600,0009,675,900,0009,835,600,000
Cost Of Revenue2,404,200,0002,310,400,0002,533,400,000
Gross Profit———
Research And Development Expenses1,778,600,0002,041,800,0002,462,000,000
General And Administrative Expenses2,433,600,0002,403,700,0002,549,700,000
Operating Expenses8,334,100,0007,769,900,0008,538,800,000
Operating Income———
Net Income1,292,900,0001,632,200,0001,161,100,000
Earnings Per Share Basic8.8311.218.02
Earnings Per Share Diluted8.7911.187.97
Weighted Average Shares Outstanding Basic146,500,000145,600,000144,700,000
Weighted Average Shares Outstanding Diluted147,100,000145,900,000145,600,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents3,008,500,0002,375,000,0001,049,900,000
Marketable Securities Current807,200,000—0
Accounts Receivable1,342,400,0001,404,800,0001,664,100,000
Inventories2,168,100,0002,460,500,0002,527,400,000
Non Trade Receivables———
Other Assets Current1,123,300,000752,500,0001,182,000,000
Total Assets Current8,974,100,0007,456,800,0006,859,300,000
Marketable Securities Non Current431,900,000—0
Property Plant And Equipment3,055,400,0003,181,300,0003,309,700,000
Other Assets Non Current750,600,000560,500,000745,000,000
Total Assets Non Current1,236,700,0001,366,100,0003,729,700,000
Total Assets29,439,500,00028,049,300,00026,844,800,000
Accounts Payable432,000,000424,200,000403,300,000
Deferred Revenue———
Short Term Debt01,748,600,000150,000,000
Other Liabilities Current2,802,600,0002,807,700,0002,623,600,000
Total Liabilities Current3,349,400,0005,528,800,0003,434,300,000
Long Term Debt6,286,800,0006,295,800,0006,938,200,000
Other Liabilities Non Current748,500,000732,300,000781,100,000
Total Liabilities Non Current7,833,300,0005,804,500,0008,611,100,000
Total Liabilities11,182,700,00011,333,300,00012,045,400,000
Common Stock100,000100,000100,000
Retained Earnings20,552,700,00019,259,800,00017,627,600,000
Accumulated Other Comprehensive Income-182,000,000-136,200,000-153,700,000
Total Shareholders Equity18,256,800,00016,716,000,00014,799,400,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization779,900,000673,200,000494,800,000
Share Based Compensation Expense290,800,000291,200,000264,200,000
Other Non Cash Income Expense-68,300,000-159,600,000-148,200,000
Change In Accounts Receivable-102,700,000-222,300,000-61,300,000
Change In Inventories64,700,000273,800,000130,900,000
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable———
Change In Other Liabilities-248,000,000-178,700,000-73,900,000
Cash From Operating Activities2,204,600,0002,875,500,0001,547,200,000
Purchases Of Marketable Securities1,258,300,00005,140,700,000
Sales Of Marketable Securities23,000,00007,380,800,000
Acquisition Of Property Plant And Equipment153,800,000153,700,000277,000,000
Acquisition Of Business01,074,800,0006,926,100,000
Other Investing Activities-42,900,0004,700,00011,300,000
Cash From Investing Activities-1,371,100,000-799,200,000-4,101,000,000
Tax Withholding For Share Based Compensation10,000,00031,300,00044,300,000
Payments Of Dividends———
Issuance Of Common Stock———
Repurchase Of Common Stock—00
Issuance Of Long Term Debt1,733,100,0000997,200,000
Repayment Of Long Term Debt1,750,000,000——
Other Financing Activities5,000,000-2,200,000-6,000,000
Cash From Financing Activities-301,900,000-683,500,000149,300,000
Change In Cash531,600,0001,392,800,000-2,404,500,000
Cash At End Of Period3,008,500,0002,375,000,0001,049,900,000
Income Taxes Paid864,000,000355,100,000185,400,000
Interest Paid264,100,000245,400,000252,200,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share8.8311.218.02
Price To Earnings Ratio19.930913.641432.2656
Earnings Growth Rate-21.23139.7756-61.7366
Price Earnings To Growth Ratio-0.93880.343-0.5226
Book Value Per Share124.6198114.8077102.2764
Price To Book Ratio1.41221.3322.5301
Ebitda3,204,300,0002,910,800,0002,088,200,000
Enterprise Value29,060,835,00027,934,552,00043,482,319,000
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio0.34440.48120.479
Capital Expenditures654,000,000544,800,000505,900,000
Free Cash Flow1,550,600,0002,330,700,0001,041,300,000
Return On Equity0.07080.09760.0785
One Year Beta0.5730.61480.7898
Three Year Beta0.62980.82340.7729
Five Year Beta0.70080.82070.826
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
ALEXANDER SUSAN HEVP Chief Legal Officer2026-02-138,450A8,450
Godbout SeanChief Accounting Officer2026-02-131,800A1,800
Gregory GingerEVP, Human Resources2026-02-138,025A8,025
Grogan JaneHead of Research2026-02-138,450A8,450
Izzar RachidHead of Global Product Strat.2026-02-137,390A7,390
This is a preview of the latest data. Subscribe to access the full data.
Senate Trading
Name Of Reporting PersonType Of Reporting PersonReport DateTransaction TypeTransaction DateOwner TypeAmount
Sheldon WhitehouseSenator2019-04-17Sale (Full)2019-03-22Spouse$1,001 - $15,000
Sheldon WhitehouseSenator2018-02-13Sale (Full)2018-01-08Joint$1,001 - $15,000
Sheldon WhitehouseSenator2017-01-11Sale (Partial)2016-12-23Joint$1,001 - $15,000
Sheldon WhitehouseSenator2017-01-11Sale (Full)2016-12-13Self$15,001 - $50,000
Sheldon WhitehouseSenator2016-08-11Purchase2015-08-10Self$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Gilbert Cisneros2026-02-13CA31Purchase2026-01-30—$1,001 - $15,000
Rob Bresnahan2025-06-09PA08Purchase2025-05-15—$1,001 - $15,000
Rob Bresnahan2025-05-08PA08Sale2025-04-08—$1,001 - $15,000
Rob Bresnahan2025-03-27PA08Purchase2025-02-25—$1,001 - $15,000
Daniel Goldman2023-04-17NY10Sale (Partial)2023-03-06—$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
BRAIDWELL LP2025-12-3120,362,043115,700175.99
WFA of San Diego, LLC2025-12-3144,525253175.9881
Camarda Financial Advisors, LLC2025-12-312,333,09913,257175.99
LAZARD ASSET MANAGEMENT LLC2025-12-318,117,18746,123175.99
Cetera Investment Advisers2025-12-314,136,35123,503175.9925
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
EMPOWER FUNDS, INC.2025-12-31Institutional ClassMXXJX655,000601,705.130.1097
EMPOWER FUNDS, INC.2025-12-31Investor ClassMXSDX655,000601,705.130.1097
EMPOWER FUNDS, INC.2025-12-31Institutional ClassMXYKX39,1006,881,209.090.3421
EMPOWER FUNDS, INC.2025-12-31Investor ClassMXMGX39,1006,881,209.090.3421
EMPOWER FUNDS, INC.2025-12-31Institutional ClassMXKWX21,7063,820,038.950.0413
This is a preview of the latest data. Subscribe to access the full data.